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INTRODUCTION
Adequate management of acute postoperative pain following 
major orthopedic surgery is an essential part of perioperative 
anesthetic practice to improve patient comfort and to facilitate 
early rehabilitation.1 Inadequate treatment of postoperative 
pain may have deleterious effects on postoperative pulmonary 
function and may also increase sensitivity to subsequent pain-
ful stimuli or lead to the development of chronic pain syn-
dromes.2 Children with musculoskeletal pathology often re-
quire extensive surgical interventions of the lower extremities at 
a relatively young age to correct the deformity and improve 
function. However, optimal pain assessment and management 
may be especially challenging in young children with develop-
mental disabilities due to communication difficulties and asso-
ciated comorbidities, such as epilepsy, chronic lung disease, 
and gastro-esophageal reflux.3,4
For orthopedic surgery of the lower extremities, continuous 
epidural analgesia provides several benefits, including im-
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proved recovery of gastrointestinal motility, attenuation of the 
surgical stress response, and reduced use of opioid medica-
tions.1,5 The use of adjuvants, such as clonidine, opioids, ket-
amine, and midazolam, with epidural local anesthetics im-
proves the duration and quality of analgesia and decreases the 
potential risk of systemic toxicity and seizure and the incidence 
of motor block by decreasing the dose of the local anesthetic.6,7 
However, opioids, such as fentanyl and morphine, which have 
traditionally been used as adjuvants to epidural local anesthet-
ics, are associated with side effects of pruritus, urinary reten-
tion, nausea and vomiting, and respiratory depression. Dexme-
detomidine, which is a highly selective α-2 adrenergic agonist 
with sedative and analgesic properties, has recently been used 
as an adjuvant to general and regional anesthesia in both adults 
and children.6-9 As of yet, dexmedetomidine has not been ap-
proved for use in the pediatric population in any country.10 
Nonetheless, adding dexmedetomidine to caudal local anes-
thetics has been recently reported to prolong postoperative an-
algesia and decrease requirements for adjuvant postoperative 
analgesics in pediatric patients undergoing lower abdominal 
and perineal surgeries.6,11-13 However, the effects of dexmedeto-
midine added to epidural local anesthetics are unclear in pedi-
atric patients undergoing major orthopedic surgery. This pro-
spective, randomized, double-blind study was designed to 
evaluate the analgesic efficacy and safety of dexmedetomidine, 
compared with fentanyl, as an adjuvant to epidural ropivacaine 
in pediatric orthopedic surgery.
MATERIALS AND METHODS 
This randomized controlled trial was approved by the institu-
tional review board of Severance Hospital, Korea (No. 4-2014-
0921) and registered at ClinicalTrials.gov (NCT02375191). Af-
ter obtaining written informed consent from the parents or 
legal guardians, we prospectively enrolled pediatric patients 
aged 3 to 12 years who were scheduled for extensive orthope-
dic surgery of the lower extremities and epidural patient-con-
trolled analgesia (PCA) between February 2015 and June 2016 
at Severance Hospital. In this study, extensive orthopedic sur-
gery was defined as at least one bone procedure at different 
anatomical levels (hip or knee). Exclusion criteria included 
history of known or suspected coagulopathy, any congenital 
anomalies at the site of the proposed epidural block, severe 
cognitive impairment with no verbal communication, history 
of allergies to any of the study drugs, and postoperative inten-
sive care unit admission. Patients were randomized into the 
fentanyl group or dexmedetomidine group using a computer-
ized randomization table. The random numbers were kept in 
opaque sealed envelopes and opened by an independent an-
esthesiologist not involved in the study, who prepared the study 
drugs in identical syringes labeled only with the drug’s serial 
number. All attending surgeons and anesthesiologists in charge 
of patient management were blinded to group allocation th-
roughout the study period. 
In the operating room, routine monitors were used. Anesthe-
sia was induced with propofol (1–2 mg/kg) and rocuronium 
(0.6 mg/kg) and maintained with sevoflurane (2–3% in 50% O2/
air mixture) and remifentanil (0.05–0.1 μg/kg/min) to achieve 
a bispectral index score of 40–60. After induction of anesthesia, 
an epidural catheter was inserted at the L2–3 or L3–4 inter-
space level by using an 18-gauge Tuohy needle with the child 
in the lateral position. Epidural space was identified by loss of 
resistance to normal saline, and a 20-gauge epidural catheter 
was inserted upward 3–4 cm into the epidural space. A load-
ing dose of 0.2% ropivacaine (0.2 mL/kg) was administered 
once the epidural catheter was secured. Thirty minutes before 
the end of the surgery, the patient received 0.2% ropivacaine 
(0.2 mL/kg) with either fentanyl (1 μg/kg) or dexmedetomi-
dine (1 μg/kg) through the epidural catheter. At this time, the 
remifentanil infusion was stopped, and the epidural PCA was 
started. The PCA device was programmed to deliver a bolus 
dose of 0.05 mL/kg ropivacaine with a lockout interval of 15 
min and background infusion of 0.15% ropivacaine (0.15 mL/
kg/h) for 48 h postoperatively. Hemodynamic parameters, in-
cluding heart rate and blood pressure, were recorded at base-
line and at 5, 10, 15, 20, and 30 min after administration of the 
study drug. Any episode of hypotension or bradycardia was 
recorded. Hypotension was defined as a systolic arterial pres-
sure <70 mm Hg+(2×age in years) and treated with fluid ther-
apy and/or ephedrine injection. Bradycardia was defined as a 
heart rate <60 beats/min and treated with atropine. At the end 
of the cast application, sevoflurane was discontinued. Emer-
gence time was recorded as the time from discontinuation of 
sevoflurane to the first evidence of any of the following: move-
ment, eye opening, crying, grimacing, or cooperation with ver-
bal commands. 
Primary endpoints were consumption of epidural ropiva-
caine and postoperative pain intensity. Secondary endpoints 
were the need for rescue analgesics, incidence of emergence 
agitation, and other adverse events (respiratory depression, 
pruritus, hypotension, bradycardia, postoperative nausea and 
vomiting, urinary retention, and oversedation). Patients were 
observed for 1 hour in the post-anesthesia care unit (PACU) 
and followed up for 48 h postoperatively at the ward. An inde-
pendent anesthesiologist blinded to group allocation assessed 
these variables. Postoperative pain was assessed using the re-
vised Face, Legs, Activity, Cry, and Consolability (r-FLACC) 
pain scale (total score, 0–10).14 If the r-FLACC pain score was 
noted at any time to be ≥4, the patient was given 0.5 μg/kg 
fentanyl (at the PACU) or 1 mg/kg tramadol (at the general 
ward). If the block was clinically inadequate or the epidural 
catheter was inadvertently dislodged, the patient was with-
drawn from the study, and fentanyl-based intravenous PCA 
was prescribed. Any interruptions in the use of epidural PCA, 
including pause or discontinuation, were recorded. Data col-
652
Adjuvants to Ropivacaine in Epidural Analgesia
https://doi.org/10.3349/ymj.2017.58.3.650
lected from the epidural PCA device (Accumate 1100, Woo 
Young Medical Co., Ltd., Seoul, Korea) included volume deliv-
ered and number of effective bolus attempts per hour. Emer-
gence delirium was assessed using the Pediatric Anesthesia 
Emergence Delirium (PAED) scale15 at 10-min intervals for 
the first 40 min after awakening from anesthesia. A total score 
of >12 at any time was considered emergence agitation. Seda-
tion was assessed using a 4-point scale (1=alert, 2=drowsy or 
opening eyes in response to verbal command, 3=asleep but 
opening eyes in response to physical stimulus such as earlobe 
tug or shaking shoulders, 4=opening eyes to painful stimulus). 
Oversedation was defined as a score of >2. 
We analyzed the results of a pilot study (10 patients) for pow-
er calculation to determine the number of patients required in 
each treatment group. On the basis of a preliminary study, the 
mean dose of ropivacaine administered by the epidural PCA 
device during the first 24 h after surgery was 0.28 mg/kg/h 
[standard deviation (SD) of 0.07 mg/kg/h]. We considered a 
20% reduction in ropivacaine consumption to be clinically 
relevant. The required sample size was 30 for each group, as-
suming an α-error of 0.05, power of 80%, and drop-out rate of 
10%. Data were analyzed using SPSS 20.0 (SPSS Inc., Chicago, 
IL, USA) and expressed as mean±SD or median (upper and 
lower quartiles), as appropriate. Continuous variables were 
analyzed by independent t-test or Mann-Whitney U test, and 
categorical variables were analyzed by chi-squared test or Fish-
er’s exact test, as appropriate. Post-hoc analyses with the Bon-
ferroni correction were performed for multiple comparisons 
when repeatedly measured variables differed significantly be-
tween groups. A p value of <0.05 was considered statistically 
significant.
RESULTS 
Of the 70 patients who were assessed for eligibility, 60 patients 
met the inclusion criteria of the study and were subsequently 
randomized. After allocation, three patients were excluded due 
to inadequate epidural analgesia despite multiple boluses, un-
expected intensive care unit admission, or neurologic deficit 
(Fig. 1). Motor and sensory deficit in the left leg of a 10-year-old 
girl in the fentanyl group persisted even after withdrawing the 
catheter by 1 cm, although the symptoms resolved within a few 
hours after discontinuation of epidural PCA. The remaining 57 
patients completed the study.
Patient characteristics (age, gender, weight, body mass index, 
Fig. 1. CONSORT flow diagram.
Enrollment Assessed for eligibility (n=70)
Randomized (n=60)
Excluded (n=10)
  – Not meeting inclusion criteria (n=10)
  – Declined to participate (n=0)
Allocated to fentanyl group (n=30)
  – Received allocated intervention (n=30)
  – Did not receive allocated intervention (n=0)
Analysed (n=29)
  – Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=1)
  – Neurologic deficit
Allocated to dexmedetomidine group (n=30)
  – Received allocated intervention (n=30)
  – Did not receive allocated intervention (n=0)
Analysed (n=28)
  – Excluded from analysis (n=0)
Lost to follow-up (give reasons) (n=1)
  – Intersive care unit admission
Discontinued intervention (give reasons) (n=1)
  – Failure of adequate epidural analgesia
Analysis
Follow-up
Allocation
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underlying disease), duration of anesthesia and intraoperative 
blood loss were comparable between the two groups (Table 1). 
The most frequent surgical procedure in both groups was fem-
oral osteotomy (75%), followed by pelvic osteotomy (46%) (Ta-
ble 2). Although there was a trend of faster emergence from an-
esthesia in the fentanyl group, it was not statistically significant 
(p=0.055). There was also no difference in duration of PACU 
stay between the two groups. 
Although the total dose of epidural ropivacaine (bolus doses 
plus background infusion volume) did not differ significantly 
between groups, the mean dose of bolus epidural ropivacaine 
administered within the first 6 h after surgery was significantly 
lower in the dexmedetomidine group (Table 3). Both groups 
obtained effective pain relief, as assessed by the r-FLACC scale, 
with 16 patients in the fentanyl group and 17 patients in the 
dexmedetomidine group never scoring more than 4 (Table 4). 
The median pain score in the dexmedetomidine group was 
lower than that of the fentanyl group at postoperative 6 hr, al-
though scores were not different between the two groups from 
6 to 48 h after surgery. The number of patients needing rescue 
analgesia did not differ significantly between groups at any 
time point.
Although not statistically significant, a gradual decrease in 
heart rate was observed in the dexmedetomidine group, com-
pared to a slight increase in the fentanyl group (Fig. 2). Mean 
arterial pressure was also comparable between the two groups 
throughout the intraoperative periods (Fig. 2). Incidence of em-
ergence agitation (PAED score >12) did not differ significantly 
between groups at any time point, with 8 of the 29 patients 
(28%) in the fentanyl group and 5 of the 28 patients (18%) in the 
dexmedetomidine group developing emergence agitation (Ta-
ble 5). No episodes of respiratory depression, bradycardia, or 
hypotension were reported. Similarly, there were no statistically 
significant differences in oversedation, nausea and vomiting, 
urinary retention, and pruritus. The mean durations of hospital 
stay were 6.6±1.8 days in the fentanyl group and 7.3±2.8 days in 
the dexmedetomidine group (p=0.261).
DISCUSSION
The present study evaluated dexmedetomidine as an adjuvant 
to epidural ropivacaine in children undergoing major orthope-
dic lower extremity surgery, and found it to be safe without any 
serious side effects and to have a significantly greater analgesic 
and local anesthetic-sparing effect in the early postoperative 
period, compared to fentanyl. 
Our results are consistent with previous studies regarding 
Table 1. Demographic and Operative Data
Fentanyl group (n=29) Dexmedetomidine group (n=28) p value
Age (yrs) 9.0 (3.1–12.0) 9.0 (5.8–12.0) 0.742
Weight (kg) 25.0 (13.4–56.9) 25.7 (14.1–49.3) 0.690
Gender (male/female) 16/13 15/13 0.903
Body mass index (kg/m2) 17.1±4.2 16.9±3.4 0.882
Diagnosis 0.475
Cerebral palsy 26 23
Syndrome with cognitive impairment 1 2
Other 2 3
Spasticity 0.878
Diplegia 12 10
Quadriplegia 9 6
Triplegia 2 4
Hemiplegia 2 3
Duration of anesthesia (min) 345.9±132.9 330.6±132.3 0.672
Duration of operation (min) 283.3±140.0 284.4±120.8 0.978
Intraoperative blood loss (mL) 241±186 260±299 0.775
Emergence time (min) 9.1±4.6 11.9±4.9 0.055
Duration of PACU stay (min) 49.7±12.6 49.7±14.3 0.994
PACU, post-anesthesia care unit. 
Values are expressed as mean±SD, median (range) or number of patients.
Table 2. Surgical Procedures
Level Type of procedure n
Pelvis Pelvic osteotomy 26
Hip
Psoas tenotomies 18
Adductor tenotomies 37
Femur Femoral derotation osteotomy 43
Knee Hamstrings tenotomies 15
Tibia Gastrocnemius slides 20
Ankle and foot
Calcaneal osteotomy 9
Achilles lengthening 12
Values are expressed as number of procedures.
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the synergic analgesic effect of dexmedetomidine when added 
to local anesthetics via caudal, epidural, or intrathecal route.6,8 
Dexmedetomidine is a potent α-2 adrenergic agonist with an 
affinity eight times greater than that of clonidine and is associ-
ated with rapid onset of sensory block, prolonged local anes-
thetic action, and decreased postoperative pain intensity in 
Table 3. Consumption of Epidural Ropivacaine by Patient-Controlled Analgesia and Background Infusion
Fentanyl group (n=29) Dexmedetomidine group (n=28) p value
Epidural ropivacaine given as bolus doses (mg/kg/hr)
0–6 hr 0.053±0.039 0.029±0.030* 0.012
6–12 hr 0.046±0.032 0.041±0.037 0.580
12–24 hr 0.050±0.028 0.065±0.043 0.129
24–48 hr 0.058±0.032 0.074±0.048 0.142
Epidural ropivacaine given as bolus doses plus background infusion (mg/kg/hr)
0–6 hr 0.276±0.060 0.265±0.091 0.604
6–12 hr 0.270±0.057 0.275±0.090 0.802
12–24 hr 0.275±0.051 0.299±0.085 0.218
24–48 hr 0.246±0.051 0.253±0.037 0.598
Results are expressed as mean±SD. 
*p<0.05 vs. fentanyl group.
Table 4. Postoperative Pain Scores and Need for Rescue Analgesics
Fentanyl group (n=29) Dexmedetomidine group (n=28) p value
r-FLACC score
PACU 2.0 (0–5.0) 0 (0–3.0) 0.098
6 hr 1.0 (0–3.0) 0 (0–1.0)* 0.039
12 hr 3.0 (1.3–3.8) 3.0 (1.0–4.8) 0.604
24 hr 1.0 (0–3.0) 2.0 (1.0–3.0) 0.268
48 hr 0.5 (0–2.3) 1.0 (0–2.0) 0.546
Need for rescue analgesic
PACU 2 0 0.491
1–6 hr 5 2 0.423
6–12 hr 12 10 0.661
12–24 hr 9 11 0.514
24–48 hr 10 9 0.851
PACU, post-anesthesia care unit; r-FLACC, revised Face, Legs, Activity, Cry, Consolability pain scale.
Results are expressed as median (interquartile range) or number of patients. 
*p<0.05 vs. fentanyl group.
Fig. 2. Hemodynamic changes after administration of the study drug. Baseline: before administration of the study drug, group F: fentanyl group, group 
D: dexmedetomidine group.
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both adults and children when used.6,8,16 Although the precise 
mechanisms are not well understood, the wide distribution of 
α-2 adrenergic receptors in the central and peripheral ner-
vous systems play a key role in mediating the effects of neur-
axial dexmedetomidine. Dexmedetomidine causes local va-
soconstriction and hyperpolarization, delaying the absorption 
of local anesthetics and prolonging their effects.17-19 Another 
possible mechanism is its central analgesic effect through spi-
nal and supraspinal actions, inhibiting the activation of spinal 
astrocytes and microglia, decreasing the release of nocicep-
tive substances, and regulating nociceptive transmission.20,21 
After epidural administration, dexmedetomidine rapidly dif-
fuses into the cerebrospinal fluid and reaches binding sites in 
the spinal cord because of its lipophilicity, and its analgesic 
effect is up to five times greater with epidural administration 
compared with systemic administration.22
When adding an adjuvant to epidural local anesthetics in 
children, the most important issues should be the safety and 
side-effect profile of the drug, as well as using the lowest effec-
tive dose. Aside from the special considerations that should be 
kept in mind with the pediatric population, there are addition-
al aspects to consider in children undergoing extensive lower 
extremity orthopedic surgery. As seen in the results of the pres-
ent study, the majority of patients requiring extensive ortho-
pedic procedures are often diagnosed with cerebral palsy or 
syndromes with cognitive impairment. The daunting task of 
assessing pain in young children is greater in this special pa-
tient population, as well as the potential of deleterious effects 
of opioids or local anesthetic toxicity. The r-FLACC pain scale 
is useful in these patients, as certain characteristic descriptors, 
such as verbal outbursts, tremors, increased spasticity, jerking 
movements, and respiratory pattern changes, such as breath 
holding and grunting, are included.14,23 The most important 
finding of the present study is that the r-FLACC pain score at 
postoperative 6 h was significantly lower for patients who re-
ceived dexmedetomidine than for those receiving fentanyl. 
Moreover, the required bolus doses of ropivacaine were de-
creased by roughly 50% during the first 6 h after surgery when 
dexmedetomidine was used, compared to fentanyl. Postopera-
tive pain is usually most intense in the early postoperative peri-
od, and the fact that bolus attempts with PCA was decreased by 
nearly 50% during this period seems to reflect the effectiveness 
of dexmedetomidine as an adjuvant to epidural ropivacaine. 
Bolus doses of epidural ropivacaine during the first postopera-
tive 6 hours were lower in the dexmedetomidine group than in 
the fentanyl group, whereas the total doses of epidural ropiva-
caine were not significantly different during the first 6 hours af-
ter surgery in both groups. This can be interpreted as a result of 
the small amount of bolus doses compared to the total dose.
The dose of dexmedetomidine used in the present study was 
chosen based on several recent dose-finding studies. In a re-
cent meta-analysis, caudally administered dexmedetomidine 
as an adjuvant to local anesthetic was reported to significantly 
prolong postoperative analgesia, compared to local anesthetic 
alone, in pediatric patients.6 Interestingly, there was no differ-
ence in analgesia between children receiving 2 μg/kg and 1 μg/
kg of dexmedetomidine upon subgroup analysis. Similarly an-
other study reported that time to first analgesia requirement, 
postoperative pain scores, and analgesic requirement over 24 h 
were comparable between patients receiving 2 μg/kg or 1 μg/kg 
caudal dexmedetomidine along with 0.25% bupivacaine.13 In a 
study comparing the postoperative analgesic effect of three 
dexmedetomidine doses (0.5, 1, and 1.5 μg/kg) added to 0.2% 
ropivacaine with that of ropivacaine alone, all three doses of 
caudal dexmedetomidine were similarly effective in preventing 
postoperative pain in children.12 However, these three afore-
mentioned studies only included children undergoing either 
urologic or lower abdominal surgery. Although epidural anal-
gesia is the preferred modality for postoperative pain manage-
ment after major lower extremity surgery in children, the dose 
and role of epidural dexmedetomidine is not well known in this 
patient population. Based on the results of previous dose-find-
ing studies of caudal dexmedetomidine,12,13 1 μg/kg epidural 
dexmedetomidine was used in the present trial.
Dose-dependent adverse effects of dexmedetomidine in-
clude hypotension, bradycardia, and sedation.24 In our study, 
we observed a clinically acceptable decrease in heart rate and 
mean arterial pressure during the 30 minutes during which pa-
tients received 1 μg/kg epidural dexmedetomidine. Reported-
ly, 1–2 μg/kg caudal dexmedetomidine given as an adjuvant is 
associated with prolonged sedation, but without delayed dis-
charge from the PACU due to oversedation.12,13 Although there 
Table 5. Postoperative Adverse Events
Fentanyl group (n=29) Dexmedetomidine group (n=28) p value
Emergence agitation 8 5 0.381
Respiratory depression 0 0
Bradycardia 0 0
Hypotension 0 0
Oversedation 0 2 0.237
Nausea and vomiting 7 10 0.340
Urinary retention 3 2 1.000
Pruritus 0 0
Values represent number of patients.
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was a trend of prolonged emergence time with dexmedetomi-
dine, compared to fentanyl, in our present study (9.1±4.6 min-
utes vs. 11.9±4.9 minutes), the difference was not statistically 
significant and also did not seem to be clinically relevant. 
Despite the clinically safe results observed in our study with 
regards to possible adverse effects of dexmedetomidine, we 
were not able to find any difference in respiratory depression, 
nausea and vomiting, urinary retention, or pruritis between the 
two groups. Although adding 0.4 μg/kg/h epidural fentanyl to 
local anesthetic provided better analgesia in children who un-
derwent femoral osteotomy, this adjuvant increased pruritus, 
nausea and vomiting, and antiemetic use.25 Similarly, adding 2 
μg/mL fentanyl and 2.5 μg/mL clonidine to 0.25% bupivacaine 
(0.5 mL/kg) provided adequate analgesia in children with cere-
bral palsy after single-event multilevel surgeries,26 but was asso-
ciated with a significantly higher incidence of vomiting and ox-
ygen desaturation.26 This discrepancy might be explained by 
differences in postoperative epidural analgesia regimens. Un-
like the previous studies in which adjuvants were given contin-
uously after surgery, epidural adjuvants were given only with 
the initial loading dose of ropivacaine in the present study. A 
future study comparing continuous epidural infusion of dex-
medetomidine with other adjuvants is needed to evaluate 
whether epidural dexmedetomidine is preferable over com-
monly used opioids with regards to side-effect profiles.
This study has several limitations. First, comprehensive 
pain assessment can be difficult with respect to the nature of 
pain and its inter-individual variability and subjectivity, espe-
cially in pediatric patients and those with cognitive impair-
ment. To minimize bias, the r-FLACC scale was used in the 
present trial, which is a valid and reliable measure of pain even 
in children with varying degrees of cognitive impairment.27 
Second, the subjects enrolled in the present study were not 
limited to a single etiology. As mentioned earlier, the benefits 
of using dexmedetomidine instead of opioids may be of great-
er value in pediatric patients with comorbidities. Although the 
majority of the patients who were enrolled in our study were 
diagnosed with cerebral palsy or other syndromes, a study 
conducted in a homogenous patient population may be able 
to shed more light on the potential advantages of using dex-
medetomidine over opioids. Last of all, we used single doses 
of dexmedetomidine and fentanyl as adjuvants to epidural lo-
cal anesthetics. Although lower pain scores and less local an-
esthetic bolus requirements were observed during the first 6 h 
after surgery, the difference in median pain scores were clini-
cally minimal, and the overall consumption of local anesthet-
ics with PCA was not different at any time interval between 
the two groups up to 48 h postoperatively. The present study is 
different from previous trials in that patients undergoing major 
orthopedic surgery were enrolled, compared to relatively sim-
ple urologic or abdominal operations. Considering the exten-
siveness of surgery and the following postoperative pain after 
major lower extremity surgery, differences in pain intensity and 
local anesthetic requirements may have been more significant 
if we had used continuous epidural infusion of adjuvants with 
postoperative PCAs. Future studies using continuous epidural 
dexmedetomidine infusion is needed to further evaluate the 
safety and efficacy of this drug as an epidural adjuvant in chil-
dren undergoing major surgery. 
In conclusion, our results suggest that dexmedetomidine can 
be used safely as an epidural adjuvant in children undergoing 
major lower extremity procedures when given as a single dose 
at the end of surgery. The main advantage of dexmedetomidine 
over fentanyl seems to be more effective analgesia during the 
early postoperative period, without causing any hemodynamic 
complications or oversedation. Special populations that are 
more susceptible to local anesthetic toxicity and side effects of 
opioids may benefit from using dexmedetomidine as an epi-
dural adjuvant after extensive correctional orthopedic surgery.
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